{
  "ticker": "EMD",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959563",
  "id": "02959563",
  "pages": 5,
  "price_sensitive": true,
  "date": "20250618",
  "time": "0944",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250618/pdf/06kvqz9l30j156.pdf",
  "summary": "### **Material Information Summary**  \n\n1. **Strategic Partnership**  \n   - Medibank (ASX: MPL) will fund PTSD treatment at Emyria\u2019s Perth Clinic for eligible customers (no out-of-pocket costs).  \n   - Multi-year agreement, first major private health insurer-backed PTSD program in Australia.  \n\n2. **Capital Raising**  \n   - **Placement**: $4M raised at $0.024/share (4% discount to last close, 6.15% discount to 15-day VWAP).  \n     - Tranche 1 (ASX 7.1/7.1A): ~120.2M shares ($2.88M).  \n     - Tranche 2 (subject to EGM): ~46.5M shares ($1.12M).  \n   - **Director Participation**: $197,000 (subject to approval).  \n   - **Loyalty Options**: 1 option per 4 shares held (exercise $0.05, 18-month expiry).  \n\n3. **Use of Funds**  \n   - Support Medibank program rollout and general working capital.  \n\n4. **Key Dates**  \n   - **Settlement (Tranche 1)**: ~25 June 2025.  \n   - **EGM**: August 2025 (for Tranche 2, options issuance).  \n\n5. **Other Material Info**  \n   - ANU-led study to validate clinical/economic outcomes.  \n   - National expansion planned (new clinics, partnerships).  \n\n*Omitted: Clinical details, director quotes, standard disclaimer boilerplate.*",
  "usage": {
    "prompt_tokens": 3365,
    "completion_tokens": 336,
    "total_tokens": 3701,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-17T23:47:26.644153"
}